Potential use of STAT3 inhibitors in targeted prostate cancer therapy: Future prospects

OncoTargets and Therapy

Volumn 5, Issue , 2012, Pages 119-125

  Shodeinde, Adetola L ^a   Barton, Beverly E ^a  

^a RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

Author keywords

JAK2 inhibitors; Targeted cancer therapy; Therapy development; Transcription factors

Indexed keywords

5 CHLORO N2 [1 (5 FLUORO 2 PYRIMIDINYL)ETHYL] N4 (5 METHYL 1H PYRAZOL 3 YL) 2,4 PYRIMIDINEDIAMINE; DOCETAXEL; JANUS KINASE 2; JANUS KINASE 2 INHIBITOR; LESTAURTINIB; MOMELOTINIB; N BENZYL 2 CYANO 3 (3,4 DIHYDROXYPHENYL)ACRYLAMIDE; N TERT BUTYL 3 [5 METHYL 2 [4 [2 (1 PYRROLIDINYL)ETHOXY]PHENYLAMINO] 4 PYRIMIDINYLAMINO]BENZENESULFONAMIDE; NS 018; PACRITINIB; PLACEBO; PROTEIN TYROSINE KINASE INHIBITOR; RUXOLITINIB; STAT3 PROTEIN; UNCLASSIFIED DRUG; XL 019;

ADVANCED CANCER; CANCER CHEMOTHERAPY; CANCER SURVIVAL; DRUG APPROVAL; DRUG EFFICACY; DRUG MECHANISM; DRUG PROTEIN BINDING; DRUG WITHDRAWAL; GENE MUTATION; HUMAN; MOLECULARLY TARGETED THERAPY; MYELOFIBROSIS; NONHUMAN; OVERALL SURVIVAL; PROSTATE CANCER; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; PROTEIN TARGETING; QUALITY OF LIFE; REVIEW; SIGNAL TRANSDUCTION; SOLID TUMOR;

EID: 84873908235     PISSN: 11786930     EISSN: None     Source Type: Journal    
DOI: 10.2147/OTT.S32559     Document Type: Review

References (94)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin. 2012;62(1):10-29.
2. National Cancer Institute. Prostate cancer treatment (PDQ®). Bethesda, MD: National Cancer Institute; 2011. Available from: http://www.cancer.gov/cancertopics/pdq/treatment/prostate/Patient/page4. Accessed Dec 16, 2011.
3. Denmeade SR, Isaacs JT. Programmed cell death (apoptosis) and cancer chemotherapy. Cancer Control. 1996;3(4):303-309.
4. Lou W, Ni Z, Dyer K, Tweardy DJ, Gao AC. Interleukin-6 induces prostate cancer cell growth accompanied by activation of STAT3 signaling pathway. Prostate. 2000;42(3):239-242.
5. Mora LB, Buettner R, Seigne J, et al. Constitutive activation of STAT3 in human prostate tumors and cell lines: direct inhibition of STAT3 signaling induces apoptosis of prostate cancer cells. Cancer Res. 2002;62(22):6659-6666.
6. Barton BE, Karras JG, Murphy TF, Barton A, Huang HF. Signal transducer and activator of transcription 3 (STAT3) activation in prostate cancer: direct STAT3 inhibition induces apoptosis in prostate cancer lines. Mol Cancer Ther. 2004;3(1):11-20.
7. Bowman T, Garcia R, Turkson J, Jove R. STATs in oncogenesis. Oncogene. 2000;19(21):2474-2488.
8. Darnell JE Jr. STATs and gene regulation. Science. 1997;277(5332): 1630-1635.
9. Bromberg J, Darnell JE Jr. The role of STATs in transcriptional control and their impact on cellular function. Oncogene. 2000;19(21): 2468-2473.
10. Darnell JE Jr, Kerr IM, Stark GR. JAK-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science. 1994;264(5164):1415-1421.
11. Darnell JE Jr. Transcription factors as targets for cancer therapy. Nat Rev Cancer. 2002;2(10):740-749.
12. Yu H, Jove R. The STATs of cancer: new molecular targets come of age. Nat Rev Cancer. 2004;4(2):97-105.
13. Ihle JN. STATs and MAPKs: obligate or opportunistic partners in signaling. Bioessays. 1996;18(2):95-98.
14. Aaronson DS, Horvath CM. A road map for those who don't know JAK-STAT. Science. 2002;296(5573):1653-1655.
15. Chen X, Vinkemeier U, Zhao Y, Jeruzalmi D, Darnell JE Jr, Kuriyan J. Crystal structure of a tyrosine phosphorylated STAT-1 dimer bound to DNA. Cell. 1998;93(5):827-839.
16. Barton BE, Murphy TF, Shu P, Huang HF, Meyenhofer M, Barton A. Novel single-stranded oligonucleotides that inhibit signal transducer and activator of transcription 3 induce apoptosis in vitro and in vivo in prostate cancer cell lines. Mol Cancer Ther. 2004;3(10):1183-1191.
17. Wegenka UM, Buschmann J, Lütticken C, Heinrich PC, Horn F. Acute-phase response factor, a nuclear factor binding to acute-phase response elements, is rapidly activated by interleukin-6 at the posttranslational level. Mol Cell Biol. 1993;13(1):276-288.
18. Akira S, Nishio Y, Inoue M, et al. Molecular cloning of APRF, a novel IFN-stimulated gene factor 3 p91-related transcription factor involved in the gp130-mediated signaling pathway. Cell. 1994;77(1):63-71.
19. Silvennoinen O, Schindler C, Schlessinger J, Levy DE. Ras-independent growth factor signaling by transcription factor tyrosine phosphorylation. Science. 1993;261(5129):1736-1739.
20. Zhong Z, Wen Z, Darnell JE Jr. STAT3: a STAT family member activated by tyrosine phosphorylation in response to epidermal growth factor and interleukin-6. Science. 1994;264(5155):95-98.
21. Ruff-Jamison S, Zhong Z, Wen Z, Chen K, Darnell JE Jr, Cohen S. Epidermal growth factor and lipopolysaccharide activate STAT3 transcription factor in mouse liver. J Biol Chem. 1994;269(35):21933-21935.
22. Hung W, Elliott B. Co-operative effect of c-Src tyrosine kinase and STAT3 in activation of hepatocyte growth factor expression in mammary carcinoma cells. J Biol Chem. 2001;276(15):12395-12403.
23. Zhang YW, Wang LM, Jove R, Vande Woude GF. Requirement of STAT3 signaling for HGF/SF-Met mediated tumorigenesis. Oncogene. 2002;21(2):217-226.
24. Parsons JT, Parsons SJ. Src family protein tyrosine kinases: cooperating with growth factor and adhesion signaling pathways. Curr Opin Cell Biol. 1997;9(2):187-192.
25. Irby RB, Yeatman TJ. Role of Src expression and activation in human cancer. Oncogene. 2000;19(49):5636-5642.
26. Danial NN, Rothman P. JAK-STAT signaling activated by Abl oncogenes. Oncogene. 2000;19(21):2523-2531.
27. Buettner R, Mora LB, Jove R. Activated STAT signaling in human tumors provides novel molecular targets for therapeutic intervention. Clin Cancer Res. 2002;8(4):945-954.
28. Stuhlmann-Laeisz C, Lang S, Chalaris A, et al. Forced dimerization of gp130 leads to constitutive STAT3 activation, cytokine-independent growth, and blockade of differentiation of embryonic stem cells. Mol Biol Cell. 2006;17(7):2986-2995.
29. Sriuranpong V, Park JI, Amornphimoltham P, Patel V, Nelkin BD, Gutkind JS. Epidermal growth factor receptor-independent constitutive activation of STAT3 in head and neck squamous cell carcinoma is mediated by the autocrine/paracrine stimulation of the interleukin 6/ gp130 cytokine system. Cancer Res. 2003;63(11):2948-2956.
30. Selander KS, Li L, Watson L, et al. Inhibition of gp130 signaling in breast cancer blocks constitutive activation of STAT3 and inhibits in vivo malignancy. Cancer Res. 2004;64(19):6924-6933.
31. Niwa H, Burdon T, Chambers I, Smith A. Self-renewal of pluripotent embryonic stem cells is mediated via activation of STAT3. Genes Dev. 1998;12(13):2048-2060.
32. Boeuf H, Hauss C, Graeve FD, Baran N, Kedinger C. Leukemia inhibitory factor-dependent transcriptional activation in embryonic stem cells. J Cell Bio. 1997;138(6):1207-1217.
33. Fukada T, Hibi M, Yamanaka Y, et al. Two signals are necessary for cell proliferation induced by a cytokine receptor gp130: involvement of STAT3 in anti-apoptosis. Immunity. 1996;5(5):449-460.
34. Puthier D, Bataille R, Amiot M. IL-6 up-regulates Mcl-1 in human myeloma cells through JAK/STAT rather than ras/MAP kinase pathway. Eur J Immunol. 1999;29(12):3945-3950.
35. Karni R, Jove R, Levitzki A. Inhibition of pp60c-Src reduces Bcl-xL expression and reverses the transformed phenotype of cells overexpressing EGF and HER-2 receptors. Oncogene. 1999;18(33):4654-4662.
36. Ivanov VN, Bhoumik A, Krasilnikov M, et al. Cooperation between STAT3 and c-jun suppresses Fas transcription. Mol Cell. 2001;7(3):517-528.
37. Sinibaldi D, Wharton W, Turkson J, Bowman T, Pledger WJ, Jove R. Induction of p21WAF1/CIP1 and cyclin D1 expression by the Src oncoprotein in mouse fbroblasts: role of activated STAT3 signaling. Oncogene. 2000;19(48):5419-5427.
38. Kijima T, Niwa H, Steinman RA, et al. STAT3 activation abrogates growth factor dependence and contributes to head and neck squamous cell carcinoma tumor growth in vivo. Cell Growth Differ. 2002;13(8): 355-362.
39. Lebedeva I, Rando R, Ojwang J, Cossum P, Stein CA. Bcl-xL in prostate cancer cells: effects of overexpression and down-regulation on chemosensitivity. Cancer Res. 2000;60(21):6052-6060.
40. Li X, Marani M, Mannucci R, et al. Over-expression of Bcl-xL underlies the molecular basis for resistance to staurosporine-induced apoptosis in PC-3 cells. Cancer Res. 2001;61(4):1699-1706.
41. Yoshida T, Hanada T, Tokuhisa T, et al. Activation of STAT3 by the hepatitis C virus core protein leads to cellular transformation. J Exp Med. 2002;196(5):641-653.
42. Yu Q, Geng Y, Sicinski P. Specific protection against breast cancers by cyclin D1 ablation. Nature. 2001;411(6841):1017-1021.
43. Masuda M, Suzui M, Yasumatu R, et al. Constitutive activation of signal transducers and activators of transcription 3 correlates with cyclin D1 overexpression and may provide a novel prognostic marker in head and neck squamous cell carcinoma. Cancer Res. 2002;62(12):3351-3355.
44. Bartoli M, Platt D, Lemtalsi T, et al. VEGF differentially activates STAT3 in microvascular endothelial cells. FASEB J. 2003;17(11):1562-1564.
45. Yahata Y, Shirakata Y, Tokumaru S, et al. Nuclear translocation of phosphorylated STAT3 is essential for vascular endothelial growth factor-induced human dermal microvascular endothelial cell migration and tube formation. J Biol Chem. 2003;278(41):40026-40031.
46. Niu G, Wright KL, Huang M, et al. Constitutive STAT3 activity up-regulates VEGF expression and tumor angiogenesis. Oncogene. 2002;21(13):2000-2008.
47. Yu CL, Meyer DJ, Campbell GS, et al. Enhanced DNA-binding activity of a STAT3-related protein in cells transformed by the Src oncoprotein. Science. 1995;269(5220):81-83.
48. Garcia R, Yu CL, Hudnall A, et al. Constitutive activation of STAT3 in fbroblasts transformed by diverse oncoproteins and in breast carcinoma cells. Cell Growth Differ. 1997;8(12):1267-1276.
49. Bromberg J F, Horvath CM, Besser D, Lathem W W, Darnell JE Jr. STAT3 activation is required for cellular transformation by v-src. Mol Cell Biol. 1998;18(5):2553-2558.
50. Turkson J, Bowman T, Garcia R, Caldenhoven E, De Groot R P, Jove R. STAT3 activation by Src induces specific gene regulation and is required for cell transformation. Mol Cell Biol. 1998;18(5):2545-2552.
51. Guo Z, Linn JF, Wu G, et al. CDC91L1 (PIG-U) is a newly discovered oncogene in human bladder cancer. Nat Med. 2004;10(4):374-381.
52. Barton BE, Murphy TF, Adem P, Watson RA, Irwin RJ, Huang HF. IL-6 signaling by STAT3 participates in the change from hyperplasia to neoplasia in NRP-152 and NRP-154 rat prostatic epithelial cells. BMC Cancer. 2001;1:19.
53. Frank DA. STAT signaling in cancer: insights into pathogenesis and treatment strategies. Cancer Treat Res. 2003;115:267-291.
54. Catlett-Falcone R, Dalton WS, Jove R. STAT proteins as novel targets for cancer therapy: signal transducer an activator of transcription. Curr Opin Oncol. 1999;11(6):490-496.
55. Turkson J, Jove R. STAT proteins: novel molecular targets for cancer drug discovery. Oncogene. 2000;19(56):6613-6626.
56. Konnikova L, Kotecki M, Kruger MM, Cochran BH. Knockdown of STAT3 expression by RNAi induces apoptosis in astrocytoma cells. BMC Cancer. 2003;3:23.
57. Leong PL, Andrews GA, Johnson DE, et al. Targeted inhibition of STAT3 with a decoy oligonucleotide abrogates head and neck cancer cell growth. Proc Natl Acad Sci U S A. 2003;100(7):4138-4143.
58. Lewis HD, Winter A, Murphy T F, Tripathi S, Pandey VN, Barton BE. STAT3 inhibition in prostate and pancreatic cancer lines by STAT3 binding sequence oligonucleotides: differential activity between 5′ and 3′ ends. Mol Cancer Ther. 2008;7(6):1543-1550.
59. Sen M, Tosca PJ, Zwayer C, et al. Lack of toxicity of a STAT3 decoy oligonucleotide. Cancer Chemother Pharmacol. 2009;63(6): 983-995.
60. Jing N, Zhu Q, Yuan P, Li Y, Mao L, Tweardy DJ. Targeting signal transducer and activator of transcription 3 with G-quartet oligonucleotides: a potential novel therapy for head and neck cancer. Mol Cancer Ther. 2006;5(2):279-286.
61. Said Hassane F, Saleh A F, Abes R, Gait MJ, Lebleu B. Cell penetrating peptides: overview and applications to the delivery of oligonucleotides. Cell Mol Life Sci. 2010;67(5):715-726.
62. Lewis HD, Husain A, Donnelly RJ, et al. Creation of a novel peptide with enhanced nuclear localization in prostate and pancreatic cancer cell lines. BMC Biotechnol. 2010;10:79.
63. Starr R, Hilton DJ. Negative regulation of the JAK/STAT pathway. Bioessays. 1999;21(1):47-52.
64. Naka T, Fujimoto M, Kishimoto T. Negative regulation of cytokine signaling: STAT-induced STAT inhibitor. Trends Biochem Sci. 1999;24(10):394-398.
65. Shuai K. Modulation of STAT signaling by STAT-interacting proteins. Oncogene. 2000;19(21):2638-2644.
66. Catlett-Falcone R, Landowski TH, Oshiro MM, et al. Constitutive activation of STAT3 signaling confers resistance to apoptosis in human U266 myeloma cells. Immunity. 1999;10(1):105-115.
67. Grandis JR, Drenning SD, Chakraborty A, et al. Requirement of STAT3 but not STAT1 activation for epidermal growth factor receptor-mediated cell growth In vitro. J Clin Invest. 1998;102(7):1385-1392.
68. Niu G, Heller R, Catlett-Falcone R, et al. Gene therapy with dominantnegative STAT3 suppresses growth of the murine melanoma B16 tumor in vivo. Cancer Res. 1999;59(20):5059-5063.
69. Ni Z, Lou W, Leman ES, Gao AC. Inhibition of constitutively activated STAT3 signaling pathway suppresses growth of prostate cancer cells. Cancer Res. 2000;60(5):1225-1228.
70. Quintás-Cardama A, Kantarjian H, Cortes J, Verstovsek S. Janus kinase inhibitors for the treatment of myeloproliferative neoplasias and beyond. Nat Rev Drug Discov. 2011;10(2):127-140.
71. Walz C, Cross NC, Van Etten RA, Reiter A. Comparison of mutated ABL1 and JAK2 as oncogenes and drug targets in myeloproliferative disorders. Leukemia. 2008;22(7):1320-1334.
72. Wernig G, Kharas MG, Okabe R, et al. Efficacy of TG101348, a selective JAK2 inhibitor, in treatment of a murine model of JAK2V617F-induced polycythemia vera. Cancer Cell. 2008;13(4):311-320.
73. Pardanani A, Lasho T, Smith G, Burns CJ, Fantino E, Tefferi A. CYT387, a selective JAK1/JAK2 inhibitor: in vitro assessment of kinase selectivity and preclinical studies using cell lines and primary cells from polycythemia vera patients. Leukemia. 2009;23(8): 1441-1445.
74. Hedvat M, Huszar D, Herrmann A, et al. The JAK2 inhibitor AZD1480 potently blocks STAT3 signaling and oncogenesis in solid tumors. Cancer Cell. 2009;16(6):487-497.
75. James C, Ugo V, Le Couédic J P, et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature. 2005;434(7037):1144-1148.
76. Kralovics R, Passamonti F, Buser AS, et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med. 2005;352(17):1779-1790.
77. Levine RL, Wadleigh M, Cools J, et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofbrosis. Cancer Cell. 2005;7(4):387-397.
78. Baxter EJ, Scott LM, Campbell PJ, et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet. 2005;365(9464):1054-1061.
79. Zhao R, Xing S, Li Z, et al. Identification of an acquired JAK2 mutation in polycythemia vera. J Biol Chem. 2005;280(24):22788-22792.
80. Scott LM, Tong W, Levine RL, et al. JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis. N Engl J Med. 2007; 356(5):459-468.
81. Pietra D, Li S, Brisci A, et al. Somatic mutations of JAK2 exon 12 in patients with JAK2 (V617F)-negative myeloproliferative disorders. Blood. 2008;111(3):1686-1689.
82. Pardanani A, Lasho TL, Finke C, Hanson CA, Tefferi A. Prevalence and clinicopathologic correlates of JAK2 exon 12 mutations in JAK2V617Fnegative polycythemia vera. Leukemia. 2007;21(9):1960-1963.
83. Wang YL, Vandris K, Jones A, et al. JAK2 mutations are present in all cases of polycythemia vera. Leukemia. 2008;22(6):1289.
84. Saharinen P, Takaluoma K, Silvennoinen O. Regulation of the JAK2 tyrosine kinase by its pseudokinase domain. Mol Cell Biol. 2000;20(10):3387-3395.
85. Quintás-Cardama A, Manshouri T, Estrov Z, et al. Preclinical characterization of atiprimod, a novel JAK2 and JAK3 inhibitor. Invest New Drugs. 2011;29(5):818-826.
86. US Food and Drug Administration. Jakaf (Ruxolitinib) label. Silver Spring, MD: FDA; 2011. Available from: http://www.accessdata.fda.gov/ drugsatfda_docs/label/2011/202192lbl.pdf. Accessed Jan 4, 2012.
87. ClinicalTrials.gov. Study of ruxolitinib (INCB018424) administered orally to patients with androgen independent metastatic prostate cancer. Bethesda, MD: National Institutes of Health; 2012. Available from: http://clinicaltrials.gov/ct2/show/study/NCT00638378?sect=X3015&view=results. Accessed February 13, 2012.
88. ClinicalTrials.gov. Study to assess safety, tolerability and PK of AZD1480 alone or in comb with docetaxel in patients with solid tumours. Bethesda, MD: National Institutes of Health; 2012. Available from: http://clinicaltrials.gov/ct2/show/NCT01112397?term=AZD1480&rank=2. Accessed Feb 13, 2012.
89. Pardanani A. JAK2 inhibitor therapy in myeloproliferative disorders: rationale, preclinical studies and ongoing clinical trials. Leukemia. 2008;22(1):23-30.
90. Pardanani A, Hood J, Lasho T, et al. TG101209, a small molecule JAK2-selective kinase inhibitor potently inhibits myeloproliferative disorder-associated JAK2V617F and MPLW515L/K mutations. Leukemia. 2007;21(8):1658-1668.
91. Tyner J W, Bumm TG, Deininger J, et al. CYT387, a novel JAK2 inhibitor, induces hematologic responses and normalizes inflammatory cytokines in murine myeloproliferative neoplasms. Blood. 2010; 115(25):5232-5240.
92. Hart S, Goh KC, Novotny-Diermayr V, et al. SB1518, a novel macrocyclic pyrimidine-based JAK2 inhibitor for the treatment of myeloid and lymphoid malignancies. Leukemia. 2011;25(11):1751-1759.
93. Nakaya Y, Shide K, Niwa T, et al. Efficacy of NS-018, a potent and selective JAK2/Src inhibitor, in primary cells and mouse models of myeloproliferative neoplasms. Blood Cancer J. 2011;1(7):e29.
94. Santos F P, Kantarjian HM, Jain N, et al. Phase 2 study of CEP-701, an orally available JAK2 inhibitor, in patients with primary or postpolycythemia vera/essential thrombocythemia myelofbrosis. Blood. 2010;115(6):1131-1136.